# Jackson Streeter

> Jackson Streeter is a Series A investor at DeepWork Capital backing Therapeutics and Biotechnology. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [DeepWork Capital](https://shizune.co/investors/profile/the-fan-fund)
- Location: Lexington, United States
- Total investments: 4
- Last investment: Jan 2024
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jackson-streeter-md-66a678/

Jackson Streeter is a Series A investor at DeepWork Capital in Lexington focused on Therapeutics and Biotechnology. Dr. Streeter was appointed Chief Executive Officer of the Institute for the Commercialization of Public Research in March 2016. Prior to joining the Institute, Dr. Streeter served as the CEO of Banyan Biomarkers of Alachua, FL. During his time the company received over $75M in contracts and grants with the Department of Defense and raised $10M inprivate investment for the development of a first ever blood test for traumatic brain injury.Prior to serving as CEO of Banyan Biomarkers, Dr. Streeter founded and served as CEO for PhotoThera, Inc. where he raised over $120M in private capital and was responsible for the design and management of five U.S. and international clinical trials. He was also the co-founder of American Veterinary Laser, inventor of over twenty patents and author on multiple scientific publications. Dr. Streeter has served on the following boards and executive committees: Florida Research Consortium, Governor’s Life Science Task Force for the State of Florida, FBI counter terrorism south east working group, Walter H. Coulter Center Committee at the University of Miami and the Gainesville Chamber of Commerce Board of Directors.Dr. Streeter served as an Officer in the U.S. Navy, completing a general surgery internship at Naval Regional Medical Center in Portsmouth, Virginia and then primary Flight School at Naval Air Station Pensacola, Florida. During his military service, he was the first Naval Flight Surgeon selected as a TOPGUN staff instructor, served on several overseas deployments and was awarded the Navy Achievement Medal and the Navy Commendation Medal. He earned his B.S. degree in Biology from the University of Nevada Reno and his M.D. from the University Of Nevada School Of Medicine.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 2 | 50% |
| Biotechnology | 2 | 50% |
| Medical | 1 | 25% |
| Health Care | 1 | 25% |
| Medical Device | 1 | 25% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 50% |
| Series B | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cyrano Therapeutics | Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell. The company's product (CYR-001) repurposes an approved molecule (Theophylline) for this new indication and has been tested with success in a pilot study. Eight out of the 10 patients treated had significantimprovement in taste and smell within 2 weeks with no reported side effects. The primary treatment provider will be the Otolaryngologist (Ear, Nose, and Throat specialist) and credible clinical investigators in this specialty have been identified and have expressed interest in participating in the clinical program.Cyrano Therapeutics was founded in 2014 and is headquartered in Washington, DC, USA. | $9M | Series B | Jan 16, 2024 |  |
| Genascence | Clinical-stage biotechnology company developing life-changing gene therapy products for musculoskeletal diseases | $5M | Series A | Aug 01, 2022 |  |
| Astrocyte Pharmaceuticals | Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease. | $6M | Series A | May 03, 2021 |  |
| Astrocyte Pharmaceuticals | Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease. | $5M | Series A |  |  |

4 of 4 investments shown.

## Co-investors
- [Boston Harbor Angels](https://shizune.co/investors/profile/boston-harbor-angels) — VC Fund, 1 deal together
- [CR Ventures](https://shizune.co/investors/profile/cr-ventures) — VC Fund, 1 deal together
- [DNV capital](https://shizune.co/investors/profile/dnv-capital) — VC Fund, 1 deal together
- [DREAMERS Ventures](https://shizune.co/investors/profile/dreamers-ventures) — VC Fund, 1 deal together
- [Florida Opportunity Fund](https://shizune.co/investors/profile/florida-opportunity-fund) — VC Fund, 1 deal together
- [Kyto Technology and Life Science Inc](https://shizune.co/investors/profile/kyto-technology-and-life-science-inc) — VC Fund, 1 deal together

## About DeepWork Capital

VC Fund · Orlando, United States

DeepWork Capital, a Florida-based venture capital firm, invests in high-growth early-stage companies in the technology and life science sectors through proprietary and public committed capital funds. The Firm partners with visionary entrepreneurs building world-changing companies and supports portfolio companies' successes with activeengagement. For additional information, please see https://www.deepworkcapital.com.

5 contacts available at DeepWork Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Benjamin Patz | Co-founder and Managing Partner | https://shizune.co/investors/profile/benjamin-patz |
| Jackson Streeter | Partner | https://shizune.co/investors/profile/jackson-streeter |
| Mitchel Laskey | Co-Founder and Managing General Partner | https://shizune.co/investors/profile/mitchel-j-laskey |
| Kathy Chiu | Managing Partner | https://shizune.co/investors/profile/kathy-chiu |
| Kenneth Hall | Vice President | https://shizune.co/investors/profile/kenneth-hall-8b13 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Jackson Streeter invest in?

Jackson Streeter invests primarily in Therapeutics, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jackson Streeter last invest?

The most recent investment recorded for Jackson Streeter closed in Jan 2024. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co